Ask anything about your gene panel, pathways, or drug candidates. Powered by live biological databases and multi-agent AI.
⚠️
Chat temporarily unavailable — AI synthesis quota exceeded.
🔒
AI Research Chat requires Researcher plan ($29/mo) —
Ask questions about your analysis results, compare drug candidates, and get mechanistic explanations grounded in evidence.
Upgrade →
Context loaded
Or enter a specific snapshot ID
Example conversation KRAS colorectal context
You
Why does encorafenib rank higher than cetuximab for this panel?
G
Encorafenib directly targets BRAF at the V600E mutation site identified in your panel. Cetuximab targets EGFR upstream — but the KRAS mutation present in your panel creates primary resistance to anti-EGFR therapy, making cetuximab a lower-tier candidate.
Encorafenib + cetuximab as a combination bypasses this resistance. In the BEACON-CRC trial, the encorafenib + binimetinib + cetuximab triplet achieved a ~26% objective response rate in BRAF V600E colorectal cancer (vs ~2% for standard control). PMID 31566309
You
What evidence quality is this based on?
G
The encorafenib signal is grounded in the BEACON-CRC Phase 3 trial results. Confidence score: 74%. Grounded evidence ratio for this specific claim: 100%.
The KRAS resistance mechanism for cetuximab is supported by RAS predictive-biomarker data PMID 26952655 and is now FDA-labelled guidance — highest evidence tier.
You
What does this analysis miss?
G
Three potential gaps: (1) RAS co-mutations — NRAS/HRAS co-occurrence with KRAS G12D can alter pathway feedback and isn't captured in single-gene scoring. (2) Tumor microenvironment — colorectal MSS (microsatellite stable) tumors have poor immune infiltration; checkpoint inhibitors are excluded from this panel's drug candidates but may become relevant with vaccine combinations. (3) Copy number alterations — BRAF amplification alongside V600E mutation changes the drug dose threshold for encorafenib and should be checked in the patient's CNV profile.